Oncology News Central (ONC)“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation

🚩 System Gap

US leadership in oncology clinical trials is declining, with fewer patients enrolled domestically despite continued global drug development and US commercialization demand. At the same time, ASCO 2026 showcased major therapeutic advances, underscoring a widening gap between scientific innovation and equitable trial access and participation.

Professional Impact

• Trial participation is reframed as standard care rather than an optional pathway, particularly when patients exhaust standard therapies.
• Declining US enrollment in international trials raises concerns about representation, access, and long-term competitiveness in oncology research.
• Cancer centers are being pushed toward a “dual mandate” model:
  • Drive scientific discovery and clinical trials
  • Demonstrate measurable impact on community outcomes and life expectancy
• Outreach and engagement are emerging as core scientific disciplines, not peripheral activities, with increasing emphasis on data-driven population health integration.
• Advances in AI, machine learning, and socio-molecular data integration may reshape how clinical questions are defined and how impact is measured.
• Institutional success is shifting from publication and trial metrics alone to real-world outcomes, including screening rates, survival improvements, and community-level disparities.

Action Items

• Normalize clinical trial discussions as part of standard oncology care, especially in late-line settings.
• Prioritize US-based trial access and enrollment strategies, including reducing structural barriers for underserved populations.
• Invest in outreach and engagement infrastructure that links trial availability with community trust-building.
• Develop impact measurement frameworks beyond accrual, including:
  • Cancer-specific survival trends in local populations
  • Screening uptake and early detection rates
  • Geographic or demographic disparities in access to trials and care
• Integrate real-world data, AI tools, and socio-demographic “omics” into research design and population targeting.
• Align institutional incentives with community-level outcomes, not just trial volume or grant performance.